Integrated biomarker strategies in immuno-oncology

JOINT EVENT:25^th World Congress on CANCER SCIENCE AND THERAPY & 10^th World Congress on BIOMARKERS & CLINICAL RESEARCH

October 18-20, 2017 Baltimore, USA

Kamala K Maddali

Cancer Genetics Inc., USA

Keynote: J Cancer Sci Ther

Abstract :

Immunotherapy enables the immune system to recognize tumors; insights into immunotherapy biomarker testing, especially PD-L1 IHC and; choosing the best patients for immunotherapy with the use of integrated biomarker panels. Combination regimens of immuno-oncology agents and targeted drugs may represent the next generation of cancer treatments and could result in improved outcomes and prolonged patient survival. This talk will focus on immunooncology advancements and a review of latest drug targets. In addition to the underlying science, we will focus on the practical aspects of targeting the PD1:PD-L1 interaction. We will discuss our perspectives of supporting PD-L1 as a pharmacodynamic end point and companion diagnostic. Additionally, we will focus on case studies, where we monitored PD-L1 expression and the variable sensitivity, specificity and dynamic range of three anti-PD-L1 antibodies in a cohort of 52 primary DLBCL patients. CGI believes that this work is essential in developing durable and reliable immune biomarkers and companion diagnostics for selecting lymphoma patients most likely to benefit from immune-checkpoint therapy.

Biography :

Kamala K Maddali is currently the Vice President of Biopharma Collaborations, Market Development and Companion Diagnostics at Cancer Genetics Inc, Rutherford, NJ. Cancer Genetics, Inc., (CGI) is a leader in the field of Personalized Medicine, offering diagnostic products and services that enable precision medicine in the field of Oncology. She holds a DVM PhD, in Pharmacology from University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N G Ranga Agricultural University in India. She brings over 10 years of extensive experience of global P&L scientific and commercial management of clinical biomarker and companion diagnostics (CDx) services covering personalized medicine strategy. She brings a lot of strategic values from her previous roles at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics.